AliveX utilizes artificial intelligence and multi-omics data integration to enhance Model-Informed Drug Development (MIDD) for immune-mediated diseases, aiming to increase the success rate of drug development while reducing costs and time. The platform addresses the challenge of low success rates in drug development by leveraging computational biology to discover novel biomarkers and drug targets.
Funding
Funding not disclosed
Founders
Product
Problem
Drug development for immune-mediated diseases faces high failure rates due to the complexity of biological systems and the difficulty in identifying effective drug targets and biomarkers. Traditional drug development processes often lack comprehensive data integration and advanced computational modeling, leading to inefficient clinical trials and increased costs.
Solution
AliveX Biotech offers an AI-powered platform that integrates multi-omics data with computational biology and Model-Informed Drug Development (MIDD) to improve drug development outcomes for immune-mediated diseases. The platform leverages large-scale multi-omics data, an immunology knowledge graph, and AI-driven analytics to discover novel biomarkers and drug targets. By combining these elements, AliveX aims to provide deeper insights into biological systems, enabling more efficient and successful drug development processes. The platform's data intelligence and computational systems biology capabilities facilitate the identification of predictive biomarkers and the design of targeted therapies.
Target Audience
The primary target audience includes biotechnology and pharmaceutical companies, as well as academic institutions, involved in drug discovery and development for immune-mediated diseases.
Features
- Multi-omics data integration, including genomics, proteomics, and metabolomics
- AI-powered analytics for biomarker and drug target discovery
- Immunology knowledge graph for contextualizing multi-omics data
- Computational systems biology for mechanistic modeling and simulation
- Model-Informed Drug Development (MIDD) framework for optimizing clinical trial design
- Predictive modeling of drug response and patient stratification